Evaluation of the effectiveness of adjuvant chemotherapy for locally advanced gastric cancer in real clinical practice
- Authors: Belyak N.P1,2, Orlova R.V1,2, Kutukova S.I1,3, Zhukova N.V1,2, Borozdina S.A2
-
Affiliations:
- City Clinical Oncology Dispensary
- St. Petersburg State University
- Pavlov University
- Issue: Vol 27, No 7 (2020)
- Pages: 41-45
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312715
- DOI: https://doi.org/10.18565/pharmateca.2020.7.41-45
- ID: 312715
Cite item
Abstract
Full Text
About the authors
N. P Belyak
City Clinical Oncology Dispensary; St. Petersburg State University
Email: drnpb@mail.ru
Cand. Sci. (Med.), Oncologist at the Chemotherapy Department № 11, City Clinical Oncology Dispensary; Teaching Assistant at the Department of Oncology, St. Petersburg State University 56 Prospekt Veteranov, St. Petersburg 198255, Russian Federation
R. V Orlova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
S. I Kutukova
City Clinical Oncology Dispensary; Pavlov UniversitySt. Petersburg, Russia
N. V Zhukova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
S. A Borozdina
St. Petersburg State UniversitySt. Petersburg, Russia
References
- Sasako M., Sakuramoto S., Katai H., et ai. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery aione in stage II or III gastric cancer. J Ciin Oncol. 2011;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908.
- Bang Y.J, Kim Y.W., Yang H.K., et ai. Adjuvant capecitabine and oxaiipiatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-iabei, randomised controiied triai. Lancet. 2012;379(9813):315-21. doi: 10.1016/ S0140-6736(11)61873-4.
- Noh S.H., Park S.R., Yang H.K., et ai. Adjuvant capecitabine pius oxaiipiatin for gastric cancer after D2 gastrectomy(CLASSIC): 5-year foiiow-up of an open-iabei, randomised phase 3 triai. Lancet. Oncoi. 2014;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5.
- Nakajima T, Nashimoto A., Kitamura M., et ai. Adjuvant mitomycin and fiuorouracii foiiowed by orai uracii pius tegafur in serosa-negative gastric cancer: a randomised triai. Gastric Cancer Surgicai Study Group. Lancet. 1999;354(9 1 75): 273-77.
- Nashimoto A., Nakajima T., Furukawa H., et ai. Randomized triai of adjuvant chemotherapy with mitomycin,fiuorouracii, and cytosine arabinoside foiiowed by orai fiuorouracii in serosa-negative gastric cancer: Japan Ciinicai Oncoiogy Group 9206-1. J Ciin Oncoi. 2003;21(12):2282-87. doi: 10.1200/JCO.2003.06.103.
- Bouche O., Ychou M., Burtin P, et ai. Adjuvant chemotherapy with 5-fiuorouracii and cispiatin compared with surgery aione for gastric cancer: 7-year resuits of the FFCD randomized phase III triai (8801). Ann Oncoi. 2005;16(9):1488-97. doi: 10.1093/annonc/mdi270.
- De Vita F, Giuiiani F, Orditura M., et ai. Adjuvant chemotherapy with epirubicin, ieucovorin, 5-fiuorouracii and etoposide regimen in resected gastric cancer patients: a randomized phase III triai by the Gruppo Oncoiogico Itaiia Meridionaie (GOIM 9602 Study). Ann Oncoi. 2007;18(8):1354-58.
- Di Costanzo F, Gasperoni S., Manzione L., et ai. Adjuvant chemotherapy in compieteiy resected gastric cancer: a randomized phase III triai conducted by GOIRC. J Nati Cancer Inst. 2008;100(6):388-98. doi: 10.1093/jnci/ djn054.
- Kuiig J., Koiodziejczyk P, Sierzega M., et ai. Adjuvant chemotherapy with etoposide, adriamycin and cispiatin compared with surgery aione in the treatment of gastric cancer: a phase III randomized, muiticenter, ciinicai triai. Oncoiogy. 2010;78(1):54-61.
- Buyse M.E., Pignon J., GASTRIC. Meta-anaiyses of randomized triais assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Ciin Oncoi. 2009;27(15S):4539.
- Paoietti X., Oba K., Burzykowski T., et ai.; for Giobai Advanced/Adjuvant Stomach Tumor Research Internationai Coiiaboration (GASTRIC) Group. Benefit of adjuvant chemotherapy for resectabie gastric cancer: a meta-anaiysis. JAMA. 2010;303(17):1729-37.
- Rawia P, Barsouk A. Epidemioiogy of gastric cancer: giobai trends, risk factors and prevention. Prz. Gastroenteroi. 2019;14(1):26-38. doi: 10.5114/pg.2018.80001.
- Sitarz R., Skierucha M., Mieiko J., Offerhaus G.J.A., Maciejewski R., Poikowski W.P Gastric cancer: epidemioiogy, prevention, ciassification, and treatment. Cancer Manag Res. 2018;10:239-48. doi: 10.2147/CMAR.S149619.